Stock analysts at Needham & Company LLC began coverage on shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) in a research note issued on Monday. The firm set a “buy” rating and a $32.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 34.91% from the company’s current price.
A number of other research firms also recently weighed in on RYTM. Bank of America Corporation began coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set a “buy” rating on the stock. Cowen and Company began coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set an “outperform” rating on the stock.
Shares of Rhythm Pharmaceuticals (RYTM) opened at 23.72 on Monday. The firm’s market capitalization is $618.48 million. The company has a 50-day moving average price of $24.23 and a 200 day moving average price of $24.23. Rhythm Pharmaceuticals has a one year low of $21.38 and a one year high of $33.81.
WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/10/30/rhythm-pharmaceuticals-inc-rytm-coverage-initiated-at-needham-company-llc.html.
In other Rhythm Pharmaceuticals news, insider Bros. Advisors Lp Baker purchased 885,000 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $15,045,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider James E. Flynn purchased 355,000 shares of the business’s stock in a transaction dated Tuesday, October 10th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,035,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 1,285,000 shares of company stock worth $21,845,000 in the last 90 days.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
What are top analysts saying about Rhythm Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rhythm Pharmaceuticals Inc. and related companies.